Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3953362 | 0.83 | OPRM1 (0.43) | ALDH1A1 | |
| SCHEMBL2989048 | 0.79 | OPRM1 (0.44) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL2984883 | 0.79 | OPRM1 (0.44) | ALDH1A1 | |
| SCHEMBL3959432 | 0.75 | OPRM1 (0.40) | KCNH2 | |
| SCHEMBL4834221 | 0.75 | OPRD1 (0.42) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL19310680 | 0.75 | SLC6A4 (0.46) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4290387 | 0.74 | HRH3 (0.52) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3686055 | 0.74 | CYP11B2 (0.49) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3962571 | 0.73 | LMNA (0.37) | HRH3 | |
| SCHEMBL2482817 | 0.71 | SLC6A4 (0.48) | CYP1A2CYP3A4CYP2D6CYP2C19CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776880-B2 | Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-08-17 | — | — | US | claimed |
| CN-101573113-A | Derivatives of pyridine, indolizine and quinolizine, preparation thereof and therapeutic use thereof | SANOFI AVENTIS (FR) | 2009-11-04 | — | — | CN | claimed |
| US-20090258899-A1 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-15 | — | — | US | claimed |
| US-20100267766-A1 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-10-21 | — | — | US | disclosed |
| US-7776880-B2 | Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-08-17 | — | — | US | disclosed |
| CN-101573113-A | Derivatives of pyridine, indolizine and quinolizine, preparation thereof and therapeutic use thereof | SANOFI AVENTIS (FR) | 2009-11-04 | — | — | CN | disclosed |
| US-20090258899-A1 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-15 | — | — | US | disclosed |
| EP-2077837-A2 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008037881-A2 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258899-A1 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INMT, IDO1, NQO2 | ALDH1A1 1508/4885CYP1A2 62/4885CYP3A4 112/4885 |
| US-20100267766-A1 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INMT, IDO1, NQO2 | ALDH1A1 1508/4885CYP1A2 62/4885CYP3A4 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.